Vivos Inc. Reports Revenue Increase but Faces Gross Loss and Higher Net Loss for Nine Months Ending September 30, 2025

Vivos Inc. reported its financial results for the nine months ending September 30, 2025, revealing a significant increase in revenue compared to the same period in 2024. The company generated $43,627 in revenue, up from $23,000 in the prior year, primarily from its IsoPet® therapies and related services. However, the cost of goods sold also rose sharply to $100,277 from $20,699, resulting in a gross loss of $56,650, compared to a gross profit of $2,301 in the previous year. The net loss for the nine-month period was $1,987,503, slightly higher than the $1,887,260 loss reported for the same period in 2024.

Operating expenses for Vivos Inc. increased to $2,012,678 from $1,944,885 year-over-year. This rise was attributed to higher research and development costs, which grew to $295,066 from $223,660, as the company ramped up efforts to develop its products in both the U.S. and India. Professional fees decreased, while general and administrative expenses increased, reflecting the company's ongoing operational adjustments. The company also reported non-operating income of $81,825, primarily from interest earned on cash accounts, compared to $55,324 in the previous year.

In terms of strategic developments, Vivos Inc. established Vivos Scientific India LLP in September 2025, aimed at expanding its manufacturing capabilities and pursuing commercialization of therapies in India. This move is part of a broader strategy to enhance its operational footprint and generate additional clinical trial data to support its FDA processes. The company has also focused on increasing its inventory of Hydrogel, which is expected to facilitate a higher volume of treatments at clinics.

As of September 30, 2025, Vivos Inc. reported total assets of $2,295,185, a slight increase from $2,233,456 at the end of 2024. The company’s cash position was $2,202,109, down from $2,212,548, indicating a need for additional funding to support ongoing operations. The company anticipates requiring approximately $3 million annually to maintain its current activities and expects to need around $9 million over the next three years to fund FDA approval processes and expand its clinical operations.

Looking ahead, Vivos Inc. remains focused on securing additional capital to sustain its operations and advance its product development initiatives. The company plans to continue leveraging its Regulation A+ offerings to raise funds while exploring strategic partnerships and licensing arrangements to facilitate its global commercialization strategy. However, the company’s ability to continue as a going concern is contingent upon its success in obtaining sufficient funding and achieving operational profitability.